+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence and predictors of elevated high-sensitivity C-reactive protein in post-myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries



Prevalence and predictors of elevated high-sensitivity C-reactive protein in post-myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries



Clinical Cardiology 40(12): 1205-1211



Elevated high-sensitivity C-reactive protein (hs-CRP) is associated with worse cardiovascular outcomes in patients with acute myocardial infarction (AMI), but little is known about the distribution of hs-CRP levels and predictors of elevated hs-CRP after AMI in the real world. Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) and Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) are prospective AMI registries in the United States that assessed hs-CRP levels 30 days after AMI. TRIUMPH additionally assessed hs-CRP levels at the time of AMI and at 6 months. Hierarchical models were built to examine predictors of elevated hs-CRP (≥2.0 mg/L) at 30 days in both registries and at 6 months after AMI in TRIUMPH. Of 3410 patients in both registries, 58.6% had elevated hs-CRP 30 days after AMI. Patients with elevated hs-CRP at 30 days were more likely to be older, female, obese, smokers, report financial difficulties, and have higher low-density lipoprotein cholesterol levels on admission, diabetes, and hypertension. In TRIUMPH, baseline hs-CRP ≥2 mg/L (n = 1301) was significantly associated with elevated hs-CRP at follow-up (P < 0.001). Similar associations were found in TRIUMPH patients with elevated hs-CRP at 6 months. Our study identified a high prevalence and several patient characteristics associated with elevated hs-CRP at 1 and 6 months after discharge. Further studies to test routine screening after AMI may be warranted to identify higher-risk patients for more aggressive secondary prevention.

(PDF emailed within 0-6 h: $19.90)

Accession: 065430626

Download citation: RISBibTeXText

PMID: 29247528

DOI: 10.1002/clc.22816


Related references

Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. International Journal of Cardiology 167(5): 1848-1853, 2014

Initiation of statin therapy after acute myocardial infarction is not associated with worsening depressive symptoms: insights from the Prospective Registry Evaluating Outcomes After Myocardial Infarctions: Events and Recovery (PREMIER) and Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) registries. American Heart Journal 166(5): 879-886, 2014

Periodontal disease in patients with acute myocardial infarction: prevalence and contribution to elevated C-reactive protein levels. American Heart Journal 147(6): 1005-1009, 2004

The polymorphism in aldehyde dehydrogenase-2 gene is associated with elevated plasma levels of high-sensitivity C-reactive protein in the early phase of myocardial infarction. Tohoku Journal of Experimental Medicine 221(2): 107-112, 2010

Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. American Journal of Cardiology 89(2): 145-149, January 15, 2002

The relationship between high sensitivity C-reactive protein level at admission and myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 34(5): 422-424, 2006

Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction. Mediators of Inflammation 2009: 932515, 2009

High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart and Vessels 18(2): 67-74, 2003

High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. American Heart Journal 204: 151-155, 2018

Concomitant impact of high-sensitivity C-reactive protein and renal dysfunction in patients with acute myocardial infarction. Yonsei Medical Journal 55(1): 132-140, 2014

The course of D-dimer, high-sensitivity C-reactive protein and pro-B-type natriuretic peptide in patients with non-ST-elevation myocardial infarction. Clinical Laboratory 57(9-10): 771-776, 2011

Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. European Heart Journal 29(10): 1241-1249, 2007

Comparison of high-sensitivity C-reactive protein level between systemic and coronary circulation in patients with acute myocardial infarction. Acta Biochimica et Biophysica Sinica 46(2): 161-162, 2014

Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. American Journal of Cardiology 107(11): 1597-1603, 2011

High-sensitivity C-reactive protein is predictive of medium-term cardiac outcome in high-risk Asian patients presenting with chest pain syndrome without myocardial infarction. Annals of the Academy of Medicine, Singapore 33(4): 407-412, 2004